October 16, 2019
Investors are reducing risk as machines and algorithms ram the sector higher with lows to follow?
Which short glass do you have, the half full of half empty one?
Perception and sentiment have merged and been regurgitated in follow-on moves
Insight is about understanding perception and is putting into context what is relevant to expectation fulfillment …
September 11, 2019
We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders
October 15, 2019
Until we reach the fork of turning overbought
News: Regenxbio (RGNX +$2.91) ongoing P1 and P2a trial for the gene therapy program, RGX-314, found the majority of patients with wet age-related macular degeneration required fewer anti-VEGF injections — the current standard of care — to manage the condition, and experienced improvement in vision and retinal thickness when they received its treatment. Ultragenyx Pharmaceutical (RARE +$1.10) the FDA has accepted for review the New Drug Application (NDA) for pipeline candidate UX007 (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). The FDA has assigned a standard review designation to the NDA and set a Prescription Drug User Fee Act (PDUFA) target date of 7/31/20.
The downside apparition stalks “our” universe and it’s not yet Halloween
In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned. It’s important for investors to identify and determine which indication is actually performance based.
September 11, 2019
We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders
August 5, 2019
A scorecard of earnings of 45 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
August 5, 2019
Volatility, algorithms, sustainability … but, geopolitical ssues are "trumping" the news Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here! News has become "something" sold into
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
6 hours 48 min ago
RegMed Investors’ (RMi) pre-open: after standing tall, futures bend over
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
